Sign In
Buy EWTX
$43.52
-0.90 (-2.03%)
At Close: Aug 07, 2026
Edgewise Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024
06:00am, Tuesday, 26'th Nov 2024
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the Piper Sandler 36th
Analysts Think There's Still Time To Get In On Edgewise
12:12pm, Monday, 30'th Sep 2024
Edgewise Therapeutics EWTX is a small-cap pharmaceutical stock that has been all the rage recently. Shares are up 55% in the last three months and up 332% over the past 52 weeks.
Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge
11:50am, Wednesday, 25'th Sep 2024
Edgewise Therapeutics EWTX is up 50% in a single session and 450% from recent lows for a reason. Its novel, oral, selective treatment for obstructive hypertrophic cardiomyopathy did remarkably well in
Analyst Think There's Still Time to Get in on Edgewise, Up 332%
09:00am, Wednesday, 25'th Sep 2024
Edgewise Therapeutics NASDAQ: EWTX is a small-cap pharmaceutical stock that has been all the rage recently. Shares are up 55% in the last three months and up 332% over the past 52 weeks.
This week, the Federal Reserve's decision to reduce interest rates by 50 basis points boosted share prices across the technology, construction, industrial, machinery, and financial sectors.
Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge
02:16pm, Thursday, 19'th Sep 2024
Edgewise Therapeutics NASDAQ: EWTX is up 50% in a single session and 450% from recent lows for a reason. Its novel, oral, selective treatment for obstructive hypertrophic cardiomyopathy did remarkably
EWTX Stock Soars on Upbeat Efficacy Data From Cardiomyopathy Studies
01:01pm, Thursday, 19'th Sep 2024
Edgewise stock soars on positive data from an early-stage study and Part A of a mid-stage study of EDG-7500 in obstructive hypertrophic cardiomyopathy patients.
Why Edgewise Therapeutics Stock Is Up 50% on Thursday
12:55pm, Thursday, 19'th Sep 2024
Edgewise's EDG-7500 shows promise as a treatment for hypertrophic cardiomyopathy. This market is currently underserved, largely because many heart drugs can cause other cardiac problems.
Edgewise Therapeutics Stock Shoots Higher On Promising Early Results For Thickened Heart Treatment
10:19am, Thursday, 19'th Sep 2024
On Thursday, Edgewise Therapeutics Inc. EWTX released announced topline data of EDG-7500 from the Phase 1 trial in healthy subjects and the single-dose arm of the Phase 2 CIRRUS-HCM trial for obstruc
Edgewise Catapults On Surprise Victory In Cardiomyopathy; Cytokinetics Shares Dip
09:22am, Thursday, 19'th Sep 2024
Edgewise Therapeutics stock skyrocketed on Thursday after a single dose of its drug improved heart function in cardiomyopathy patients.
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced top-line data of EDG-7500 from the Phase 1 trial in he
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that members of the management team will hold a live w
Edgewise Therapeutics: Strong Open Label Data Makes For A Bullish Signal
02:38pm, Monday, 05'th Aug 2024
Edgewise Therapeutics develops small molecules for myopathies, with lead molecule sevasemten in phase 3 for Becker Muscular Dystrophy. Company was founded in 2017, backed by OrbiMed, with an experienc
7 Small-Cap Stocks to Buy for Large-Scale Gains
12:25pm, Tuesday, 30'th Jul 2024
Small-capitalization companies represent high-risk endeavors. At the same time, they generally carry higher reward potential.
Here's Why Edgewise Therapeutics, Inc. (EWTX) is a Great Momentum Stock to Buy
01:00pm, Wednesday, 17'th Jul 2024
Does Edgewise Therapeutics, Inc. (EWTX) have what it takes to be a top stock pick for momentum investors? Let's find out.
